Your legal team crafts a solid partnership; prices are correct, terms are optimized, and protection is set up. Months later, the business case doesn't reconcile.
The missing value is contract leakage: the invisible drop between what was negotiated and what was delivered.
Organizations lose 9.2% of contract value to leakage, says the World Commerce and Contracting Association. This represents $18.4M lost from the bottom line for a pharma company with a $200M spend.
Leakage does not emerge spontaneously. It builds through operational decisions, missed check-ins, split execution, and then, in time, the organization will revert into being reactive, chase performance, and recover value.
What Contract Leakage Looks Like in Pharma
Leakage appears in pharma through the day-to-day execution:
A PO reflects a pricing that does not comply with the contract. A manufacturing site chooses non-approved supplier to speed up, A volume rebate is generated but not claimed/tracked
Each event is logical and individual, but in a large company, this leads to a progressive erosion of the contract. The most usual source is within standard change requests, generally through email, and based on people’s availability. A delayed approval could turn into a production, compliance issue, or batch of rejection.
Why Pharma Is More Prone to Leakage
Pharma environment heightens leakage risk:
Complex supplier ecosystem
While there are many suppliers, they're only controlled at the top level for a small subset of suppliers. Most non-core suppliers don't even go through centralized control.
Decentralized purchasing
Each function (Manufacturing, R&D, and regions) has its own agenda. Centrally negotiated deals don't always align with the execution at the individual sites.
Speed of operations and functional silos
Local sites optimize fast response, which inadvertently results in not adhering to agreed contract terms.
Regulation-centric contracts
Contracts involve regulatory requirements such as Quality, Safety, Traceability, and Cold Chain. Non-compliance means not just loss of money but also compliance issues.
In the case of pharma, contract leakage is an operational/regulatory issue.
The Three Places of Leakage Compounds
- Gaps in Contract Compliance: Breaching contractual terms is known to incur lost discounts, lost fee-capture and penalty fees - typically 5% of the contract value.
- Maverick Spending: Non-clinical departments (clinical, R&D, site teams, etc.) will use suppliers not on the agreed vendor list. This leads to compliance with blind spots and invalidated prices or quality agreements.
- Lost Rebates: Due to data fragmentation and poor contract visibility, sales volume or performance rebates are often unclaimed, estimated to cost the industry > $150M per year.
What Closing the Gap Really Requires
Eliminating contract leakage needs to focus more on improving overall execution and not just renegotiation. Pharma companies must systematically make changes in procurement contracts with the help of intelligence and automation.
Global spend interoperability
Transparency across manufacturing, R&D, clinical operations, and CDMOs so that purchases are routed through approved vendors and channelled correctly through the contract.
Embedded compliance enforcement
It is important to enforce compliance at the point of transaction, along with validating GxP and the Quality Agreements when the purchase is being made, rather than during a retrospective audit.
Continuous rebate tracking
Rebate tracking ensures that every applicable rebate, volume commitment, and incentive is received automatically and traced through the product lifecycle.
The SAP Question
A majority of the leakages in contracts at Pharma take place in the SAP environment, owing to system constraints and to the gap that still exists between humans and systems. The solution is not replacement but extension.
Intelligence layers above the SAP environment can allow the generation of live compliance attestations, anomaly detection, and automated validation without changing the workflow and increasing execution. The stability of the systems will not be compromised.
The Conversation Worth Having
Contract leakage is not transparent. It is calculable, predictable, and preventable. Pharma companies already know how to negotiate value, but it's time they also realized it.
The only required change is not just the ability to negotiate value at the table, but the ability to protect it at the point of transaction.
AI offers the necessary consistency, transparency, and control at an enterprise level, enabling automatic extraction of terms, transaction validation, tracking of rebates, and reconciliation of invoices with a higher level of accuracy. It's not strategic for pharma to leave leakage on the table; the cost and the compliance risk are too high.
The Practical Solution to Fix Contract Leakage in Pharma
There's no way to audit-fix the leakage at Pharma; they must close the execution gap. The answer is to move from inspection to systemic compliance within procurement, quality, and legal.
The answer is to insert an intelligence layer on top of SAP and its existing infrastructure that makes contract terms actionable, consistent, and auditable.
What the Fix Looks Like (Checklist):
Make contracts machine-readable
- Pricing, obligations, quality clauses, rebates, and SLAs are extracted.
- They are then translated into rules, which are then used for real-time validation.
Every transaction is validated at source
- PR/PO compared with the accepted supplier, rate, MOQ, and QA conditions.
- Transactions that do not comply are immediately blocked or flagged.
Standardize procurement across all worldwide sites
- Unified into a single system, manufacturing, R&D, clinical operations, and CDMOs
- Site-level deviations and site supplier diversification are automatically flagged.
Automate change request governance:
- CRs no longer depend on an email-based process
- SLA bound workflow with AI compared with the original contract.
Fix rebate leakages
- Through continuous monitoring of thresholds.
- Rebate claims are automatically submitted, and evidence
- Close the loop between legal, procurement, and quality
- A single platform to monitor obligations, performance, risks, and savings.
- Automated monthly contract health reports will provide an overview.
The AI-at-Scale Advantage
The pharma industry doesn't have contract leakage because people are not vigilant; instead, it has contract leakage because a human can't keep up with the number of contracts, suppliers, transactions, and compliance regulations. This implies that by AI at scale in pharma, the intention is that AI must manage operational volumes, complexities, and velocity where humans are simply outrun.
How AI Handles Scale (Checklist):
Validation of high-volume transactions
- Validate thousands of POs, PRs, invoices, and change orders in parallel
- Contracts are interpreted at speed no matter the volume
Multi-layer contract interpretation
- Reads multi-level pricing, quality clauses, and rebate buckets
- Uses the correct contract rules per site, business unit, or material type
Supplier complexity
- Monitors hundreds of thousands of suppliers, CDMOs, logistics providers
- Flags issues and non-approved suppliers immediately
Distributed site operation
- Controls behavior across the manufacturing, R&D, and clinical sites
- Allows simultaneous checking of activities across each site, regardless of speed and volume
Continuous compliance needs
- Continuously monitoring contract obligations, expiry terms, GXP status, and quality agreements
- Enables no lost audit trails, no risk of a regulatory step-down due to system strain
Rebates and incentives at volume
- Monitors rebate achievements across all materials, plants, and timeframes
- Eradicates lost opportunities from manual, dispersed tracking
Scale with minimal systems disruption
- Sits on top of SAP/Ariba/Veeva without taxing the existing infrastructure
- Can manage a burst of purchasing activity without negatively affecting its speed
